{"id":129925,"date":"2023-12-06T10:49:49","date_gmt":"2023-12-06T09:49:49","guid":{"rendered":"https:\/\/prod1-sb.designtech.space\/drug-repurposing-and-the-novo-nordisk-case\/129925\/"},"modified":"2023-12-06T10:49:49","modified_gmt":"2023-12-06T09:49:49","slug":"drug-repurposing-and-the-novo-nordisk-case","status":"publish","type":"post","link":"https:\/\/www.startupbusiness.it\/en\/drug-repurposing-and-the-novo-nordisk-case\/129925\/","title":{"rendered":"Drug repurposing and the Novo Nordisk case"},"content":{"rendered":"

Technically, it is called drug repurposing and basically indicates the repositioning of drugs<\/strong> as a result of the fact that they prove effective for pathologies that are not those for which they were originally designed. Cases of drug repurposing<\/a> are not very frequent but not very rare either, and above all they have consequences not only of a pharmaceutical type but also of an economic and social nature. The best known of these cases is certainly that of Viagra<\/strong>, which was born as a drug whose purpose was to treat angina pectoris, hypertension and other cardiovascular disorders but, it was promptly discovered, has extremely effective effects as an erection stimulant and therefore capable of curing erectile dysfunction, here the active ingredient is that of sildenafil which following the great popularity it had among the global male community has become the basis for all A series of medications created specifically to support sexual activity. Other cases include minoxidil, which was also studied as a cure for hypertension<\/strong>, and was soon found to have hair-growing abilities, and here too the global community decided to benefit from it. Another active ingredient, another repurposing was that of thalidomide which was born as a drug to combat nausea in pregnancy<\/strong>, but proved harmful for this application, it had the unexpected effectiveness of being active against myelomas. The most striking of these cases, however, is the one that has been happening in recent weeks with great economic and social impact. Here the active ingredient is that of Semaglutide was created to treat diabetes and has been found to be very effective for weight loss.<\/strong> In one part of the world, overweight and obesity are widespread, and the drug, whose trade name was originally Ozempic<\/strong> It soon became a best seller, so much so that the pharmaceutical company that produces it, the Danish Novo Nordisk, rushed to develop a version designed precisely to facilitate weight loss that took the trade name of Wegovy.<\/strong> Now, however, things are happening: in the meantime there has been an outcry from the community of people with diabetes because they now have difficulty finding the drug that is vital for them as more and more people get it prescribed for reasons related more to aesthetics than to health, thus creating a social problem that can be solved by increasing the availability of the drug and insisting on separation, On a commercial level, between the one originally created for diabetics and the one created specifically to facilitate weight loss. And precisely for this reason, the Danish company announced a few days ago an investment of more than 2 billion euros to expand its production center based in Chartres in France, news that followed that of the announcement made at the beginning of November, of another expansion project at the Danish production site in Kalundborg for a value of over 5.5 billion euros. <\/p>\n

Innovation, society, economy<\/h2>\n

Then there is the economic question because Novo Nordisk is getting very rich. The numbers are impressive: over \u20ac30 billion in turnover<\/a> expected by the end of 2023, set to become \u20ac37 billion in 2024 and \u20ac44 billion in 2026.<\/strong> It is currently the most capitalized European company with a value of more than 400 billion euros, more or less the same as the GDP of the whole of Denmark To have a term of comparison, the value of its shares has gone from about 240 Danish kroner in June 2021 just before the approval of Wegovy by the FDA (the Federal Drug Administration, the U.S. Medicines Authority) peaked at more than 700 crowns in November 2023. Today, Novo Nordisk is the European company with the largest market capitalization ahead of LVMH.<\/strong> the French luxury giant that capitalizes 350 billion euros, Nestl\u00e9, the Swiss conglomerate in the food sector that capitalizes 280 billion euros, the Dutch ASML that operates in the semiconductor sector with just over 250 billion capitalization, the other French L’Oreal with about 235 billion, the two Swiss pharmaceutical companies Roche and Novartis respectively in sixth and ninth place by capitalization value, separated from Hermes and Shell, which are seventh and eighth, the ranking of the 10 most capitalized companies in Europe is closed by the British AstraZeneca, then another pharmaceutical. Even looking at a global level, Novo Nordisk appears to be the second most capitalized pharmaceutical company in the world after the US Eli Lilly<\/strong> and before the other US Johnson & Johnson, followed by Merck (USA) and the aforementioned Roche, Novartis<\/a> and AstraZeneca. The issue is therefore of scientific, social and economic interest, also because it should be remembered that Denmark, despite being a country of the European Union, has decided not to adopt the euro, therefore the occurrence of imbalances in economic values, in one sense or another, would risk stressing the system of relationship between the value of Danish kroner and the euro which, It does provide for a possible fluctuation, but within fixed limits, just as interest rate decisions must also be taken in a coordinated manner between the ECB and the Danish central bank. What is likely to happen in the immediate future is a growth in the popularity of Wegovy, as was the case with Viagra, and therefore a continued growth in the value of Novo Nordisk as well, but what these stories show is how innovation is formed and transformed and how it is able to bring benefits. History is full of scientific discoveries that have made it possible to eradicate serious diseases or to have devices capable of diagnosing and treating diseases that were once lethal, when it comes to life science the impact on humanity is directly visible (we have also seen it happen recently with the COVID-19 vaccines<\/a>), but Even when innovation develops in other sectors, there are moments of great impact, think for example of energy, and it is particularly important that in this historical moment there are innovations of great magnitude because the challenges to be overcome are many and of historic significance<\/strong> starting with those related to climate change, the increase in the average age especially in Europe and some Asian countries, the redefinition of strategic and geopolitical balances and models. (photo: Novo Nordisk website)<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"

Drugs designed to treat certain diseases that then prove effective for others are an example of how innovation can take unexpected paths<\/p>\n","protected":false},"author":125,"featured_media":136946,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[1464,1346],"tags":[1144,1492,1331,1407],"companies":[],"journalist":[1513],"class_list":["post-129925","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-editorial","category-must-read","tag-europe-en","tag-healtcare-en","tag-innovation-en","tag-life-sciences","journalist-emil-abirascid-en"],"featured_sizes_urls":{"thumbnail":{"src":"https:\/\/www.startupbusiness.it\/wp-content\/uploads\/2024\/05\/cq5dam.web_.2000.2000.jpeg","width":150,"height":116,"crop":false,"srcset":false,"alt":""},"large":{"src":"https:\/\/www.startupbusiness.it\/wp-content\/uploads\/2024\/05\/cq5dam.web_.2000.2000.jpeg","width":1024,"height":790,"crop":false,"srcset":false,"alt":""},"2048x2048":{"src":"https:\/\/www.startupbusiness.it\/wp-content\/uploads\/2024\/05\/cq5dam.web_.2000.2000.jpeg","width":2000,"height":1543,"crop":false,"srcset":false,"alt":""}},"acf":[],"yoast_head":"\nDrug repurposing and the Novo Nordisk case<\/title>\n<meta name=\"description\" content=\"Drugs designed to treat diseases that then prove effective for others are an example of innovation that takes unexpected paths\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.startupbusiness.it\/en\/drug-repurposing-and-the-novo-nordisk-case\/129925\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Drug repurposing and the Novo Nordisk case\" \/>\n<meta property=\"og:description\" content=\"Drugs designed to treat diseases that then prove effective for others are an example of innovation that takes unexpected paths\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.startupbusiness.it\/en\/drug-repurposing-and-the-novo-nordisk-case\/129925\/\" \/>\n<meta property=\"og:site_name\" content=\"Startupbusiness.it\" \/>\n<meta property=\"article:published_time\" content=\"2023-12-06T09:49:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.startupbusiness.it\/wp-content\/uploads\/2024\/05\/cq5dam.web_.2000.2000.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"2000\" \/>\n\t<meta property=\"og:image:height\" content=\"1543\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Emil Abirascid\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@emilabirascid\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Emil Abirascid\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/drug-repurposing-and-the-novo-nordisk-case\\\/129925\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/drug-repurposing-and-the-novo-nordisk-case\\\/129925\\\/\"},\"author\":{\"name\":\"Emil Abirascid\",\"@id\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/#\\\/schema\\\/person\\\/4e2760db2cb7ca47d635ea3d8d8486dd\"},\"headline\":\"Drug repurposing and the Novo Nordisk case\",\"datePublished\":\"2023-12-06T09:49:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/drug-repurposing-and-the-novo-nordisk-case\\\/129925\\\/\"},\"wordCount\":1024,\"commentCount\":0,\"image\":{\"@id\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/drug-repurposing-and-the-novo-nordisk-case\\\/129925\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.startupbusiness.it\\\/wp-content\\\/uploads\\\/2024\\\/05\\\/cq5dam.web_.2000.2000.jpeg\",\"keywords\":[\"Europe\",\"Healtcare\",\"innovation\",\"Life Sciences\"],\"articleSection\":[\"Editorial\",\"Must Read\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/drug-repurposing-and-the-novo-nordisk-case\\\/129925\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/drug-repurposing-and-the-novo-nordisk-case\\\/129925\\\/\",\"url\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/drug-repurposing-and-the-novo-nordisk-case\\\/129925\\\/\",\"name\":\"Drug repurposing and the Novo Nordisk case\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/drug-repurposing-and-the-novo-nordisk-case\\\/129925\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/drug-repurposing-and-the-novo-nordisk-case\\\/129925\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.startupbusiness.it\\\/wp-content\\\/uploads\\\/2024\\\/05\\\/cq5dam.web_.2000.2000.jpeg\",\"datePublished\":\"2023-12-06T09:49:49+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/#\\\/schema\\\/person\\\/4e2760db2cb7ca47d635ea3d8d8486dd\"},\"description\":\"Drugs designed to treat diseases that then prove effective for others are an example of innovation that takes unexpected paths\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/drug-repurposing-and-the-novo-nordisk-case\\\/129925\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/drug-repurposing-and-the-novo-nordisk-case\\\/129925\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.startupbusiness.it\\\/wp-content\\\/uploads\\\/2024\\\/05\\\/cq5dam.web_.2000.2000.jpeg\",\"contentUrl\":\"https:\\\/\\\/www.startupbusiness.it\\\/wp-content\\\/uploads\\\/2024\\\/05\\\/cq5dam.web_.2000.2000.jpeg\",\"width\":2000,\"height\":1543,\"caption\":\"La sede di Novo Nordisk\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/\",\"name\":\"Startupbusiness.it\",\"description\":\"May the Force be with you!\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/#\\\/schema\\\/person\\\/4e2760db2cb7ca47d635ea3d8d8486dd\",\"name\":\"Emil Abirascid\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/84e46190ac811c9c62650621ceca8f65c1e967d6b06e6352fe183145dba0d7e9?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/84e46190ac811c9c62650621ceca8f65c1e967d6b06e6352fe183145dba0d7e9?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/84e46190ac811c9c62650621ceca8f65c1e967d6b06e6352fe183145dba0d7e9?s=96&d=mm&r=g\",\"caption\":\"Emil Abirascid\"},\"description\":\"Emil Abirascid (\u30a8\u30df\u30fc\u30eb\u30fb\u30a2\u30d3\u30e9\u30b7\u30c3\u30c9), giornalista, fondatore e direttore di Startupbusiness, il primo magazine sull\u2019ecosistema startup e innovazione italiano. Co-fondatore di Designtech, l\u2019hub di innovazione che avvicina il mondo del design con quello della tecnologia. Advisor di Austrian Business Agency, Emil Banca, Fondazione Symbola, Fondazione Quadrans. Partecipa regolarmente a incontri, convegni, conferenze dedicate all\u2019ecosistema dell\u2019innovazione. E\u2019 stato co-organizzatore degli Italian Innovation Day and Series che si sono svolti dal dal 2016 al 2020 nelle citt\u00e0 di Tokyo in Giappone, Melbourne, Adelaide, Perth, Canberra in Australia e Singapore e co-organizzatore dell\u2019Italy India Innovation Day di AIICP 2021 e 2022. Ha curato il volume \u2018L\u2019innovazione che non ti aspetti. Contesti e visioni per l\u2019impresa\u2019 , l\u2019edizione italiana di \u2018La startup digitale, guida pratica step by step\u2019 e ha scritto la prefazione all\u2019edizione italiana de \u2018La quarta era\u2019 di Byron Reese, ed \u00e8 co-autore di \u2018Cosa e Dove: strategie digitali di ricerca del lavoro\u2019, tutti editi da FrancoAngeli. In passato \u00e8 stato curatore di StartupDigest Italy, coordinatore scientifico del Forum per la Ricerca della Provincia Autonoma di Trento, board member di TechChill Milano advisor di di ScaleIT , ha collaborato con Il Sole 24 Ore \u00e8 stato direttore di Innov\u2019azione, bimestrale edito da Apsti, ha collaborato con Corriere Innovazione ed \u00e8 stato presidente del comitato di selezione del Premio Marzotto e advisor di Cetif-Universit\u00e0 Cattolica Milano.\",\"sameAs\":[\"https:\\\/\\\/www.abirascid.com\\\/\",\"https:\\\/\\\/www.linkedin.com\\\/in\\\/emilabirascid\",\"https:\\\/\\\/x.com\\\/emilabirascid\"],\"url\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/author\\\/emil-abirascid\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Drug repurposing and the Novo Nordisk case","description":"Drugs designed to treat diseases that then prove effective for others are an example of innovation that takes unexpected paths","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.startupbusiness.it\/en\/drug-repurposing-and-the-novo-nordisk-case\/129925\/","og_locale":"en_US","og_type":"article","og_title":"Drug repurposing and the Novo Nordisk case","og_description":"Drugs designed to treat diseases that then prove effective for others are an example of innovation that takes unexpected paths","og_url":"https:\/\/www.startupbusiness.it\/en\/drug-repurposing-and-the-novo-nordisk-case\/129925\/","og_site_name":"Startupbusiness.it","article_published_time":"2023-12-06T09:49:49+00:00","og_image":[{"width":2000,"height":1543,"url":"https:\/\/www.startupbusiness.it\/wp-content\/uploads\/2024\/05\/cq5dam.web_.2000.2000.jpeg","type":"image\/jpeg"}],"author":"Emil Abirascid","twitter_card":"summary_large_image","twitter_creator":"@emilabirascid","twitter_misc":{"Written by":"Emil Abirascid","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.startupbusiness.it\/en\/drug-repurposing-and-the-novo-nordisk-case\/129925\/#article","isPartOf":{"@id":"https:\/\/www.startupbusiness.it\/en\/drug-repurposing-and-the-novo-nordisk-case\/129925\/"},"author":{"name":"Emil Abirascid","@id":"https:\/\/www.startupbusiness.it\/en\/#\/schema\/person\/4e2760db2cb7ca47d635ea3d8d8486dd"},"headline":"Drug repurposing and the Novo Nordisk case","datePublished":"2023-12-06T09:49:49+00:00","mainEntityOfPage":{"@id":"https:\/\/www.startupbusiness.it\/en\/drug-repurposing-and-the-novo-nordisk-case\/129925\/"},"wordCount":1024,"commentCount":0,"image":{"@id":"https:\/\/www.startupbusiness.it\/en\/drug-repurposing-and-the-novo-nordisk-case\/129925\/#primaryimage"},"thumbnailUrl":"https:\/\/www.startupbusiness.it\/wp-content\/uploads\/2024\/05\/cq5dam.web_.2000.2000.jpeg","keywords":["Europe","Healtcare","innovation","Life Sciences"],"articleSection":["Editorial","Must Read"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.startupbusiness.it\/en\/drug-repurposing-and-the-novo-nordisk-case\/129925\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.startupbusiness.it\/en\/drug-repurposing-and-the-novo-nordisk-case\/129925\/","url":"https:\/\/www.startupbusiness.it\/en\/drug-repurposing-and-the-novo-nordisk-case\/129925\/","name":"Drug repurposing and the Novo Nordisk case","isPartOf":{"@id":"https:\/\/www.startupbusiness.it\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.startupbusiness.it\/en\/drug-repurposing-and-the-novo-nordisk-case\/129925\/#primaryimage"},"image":{"@id":"https:\/\/www.startupbusiness.it\/en\/drug-repurposing-and-the-novo-nordisk-case\/129925\/#primaryimage"},"thumbnailUrl":"https:\/\/www.startupbusiness.it\/wp-content\/uploads\/2024\/05\/cq5dam.web_.2000.2000.jpeg","datePublished":"2023-12-06T09:49:49+00:00","author":{"@id":"https:\/\/www.startupbusiness.it\/en\/#\/schema\/person\/4e2760db2cb7ca47d635ea3d8d8486dd"},"description":"Drugs designed to treat diseases that then prove effective for others are an example of innovation that takes unexpected paths","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.startupbusiness.it\/en\/drug-repurposing-and-the-novo-nordisk-case\/129925\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.startupbusiness.it\/en\/drug-repurposing-and-the-novo-nordisk-case\/129925\/#primaryimage","url":"https:\/\/www.startupbusiness.it\/wp-content\/uploads\/2024\/05\/cq5dam.web_.2000.2000.jpeg","contentUrl":"https:\/\/www.startupbusiness.it\/wp-content\/uploads\/2024\/05\/cq5dam.web_.2000.2000.jpeg","width":2000,"height":1543,"caption":"La sede di Novo Nordisk"},{"@type":"WebSite","@id":"https:\/\/www.startupbusiness.it\/en\/#website","url":"https:\/\/www.startupbusiness.it\/en\/","name":"Startupbusiness.it","description":"May the Force be with you!","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.startupbusiness.it\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.startupbusiness.it\/en\/#\/schema\/person\/4e2760db2cb7ca47d635ea3d8d8486dd","name":"Emil Abirascid","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/84e46190ac811c9c62650621ceca8f65c1e967d6b06e6352fe183145dba0d7e9?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/84e46190ac811c9c62650621ceca8f65c1e967d6b06e6352fe183145dba0d7e9?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/84e46190ac811c9c62650621ceca8f65c1e967d6b06e6352fe183145dba0d7e9?s=96&d=mm&r=g","caption":"Emil Abirascid"},"description":"Emil Abirascid (\u30a8\u30df\u30fc\u30eb\u30fb\u30a2\u30d3\u30e9\u30b7\u30c3\u30c9), giornalista, fondatore e direttore di Startupbusiness, il primo magazine sull\u2019ecosistema startup e innovazione italiano. Co-fondatore di Designtech, l\u2019hub di innovazione che avvicina il mondo del design con quello della tecnologia. Advisor di Austrian Business Agency, Emil Banca, Fondazione Symbola, Fondazione Quadrans. Partecipa regolarmente a incontri, convegni, conferenze dedicate all\u2019ecosistema dell\u2019innovazione. E\u2019 stato co-organizzatore degli Italian Innovation Day and Series che si sono svolti dal dal 2016 al 2020 nelle citt\u00e0 di Tokyo in Giappone, Melbourne, Adelaide, Perth, Canberra in Australia e Singapore e co-organizzatore dell\u2019Italy India Innovation Day di AIICP 2021 e 2022. Ha curato il volume \u2018L\u2019innovazione che non ti aspetti. Contesti e visioni per l\u2019impresa\u2019 , l\u2019edizione italiana di \u2018La startup digitale, guida pratica step by step\u2019 e ha scritto la prefazione all\u2019edizione italiana de \u2018La quarta era\u2019 di Byron Reese, ed \u00e8 co-autore di \u2018Cosa e Dove: strategie digitali di ricerca del lavoro\u2019, tutti editi da FrancoAngeli. In passato \u00e8 stato curatore di StartupDigest Italy, coordinatore scientifico del Forum per la Ricerca della Provincia Autonoma di Trento, board member di TechChill Milano advisor di di ScaleIT , ha collaborato con Il Sole 24 Ore \u00e8 stato direttore di Innov\u2019azione, bimestrale edito da Apsti, ha collaborato con Corriere Innovazione ed \u00e8 stato presidente del comitato di selezione del Premio Marzotto e advisor di Cetif-Universit\u00e0 Cattolica Milano.","sameAs":["https:\/\/www.abirascid.com\/","https:\/\/www.linkedin.com\/in\/emilabirascid","https:\/\/x.com\/emilabirascid"],"url":"https:\/\/www.startupbusiness.it\/en\/author\/emil-abirascid\/"}]}},"author_name":"Emil Abirascid","categories_names":["Editorial","Must Read"],"_links":{"self":[{"href":"https:\/\/www.startupbusiness.it\/en\/wp-json\/wp\/v2\/posts\/129925","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.startupbusiness.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.startupbusiness.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.startupbusiness.it\/en\/wp-json\/wp\/v2\/users\/125"}],"replies":[{"embeddable":true,"href":"https:\/\/www.startupbusiness.it\/en\/wp-json\/wp\/v2\/comments?post=129925"}],"version-history":[{"count":0,"href":"https:\/\/www.startupbusiness.it\/en\/wp-json\/wp\/v2\/posts\/129925\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.startupbusiness.it\/en\/wp-json\/wp\/v2\/media\/136946"}],"wp:attachment":[{"href":"https:\/\/www.startupbusiness.it\/en\/wp-json\/wp\/v2\/media?parent=129925"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.startupbusiness.it\/en\/wp-json\/wp\/v2\/categories?post=129925"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.startupbusiness.it\/en\/wp-json\/wp\/v2\/tags?post=129925"},{"taxonomy":"companies","embeddable":true,"href":"https:\/\/www.startupbusiness.it\/en\/wp-json\/wp\/v2\/companies?post=129925"},{"taxonomy":"journalist","embeddable":true,"href":"https:\/\/www.startupbusiness.it\/en\/wp-json\/wp\/v2\/journalist?post=129925"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}